|
|
Exchange: |
Nasdaq Small Cap |
Security
Type: |
Common |
Shares
Out: |
61,650,000 |
Market
Cap: |
241.67(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.08 - $5.47 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Omeros is a commercial-stage biopharmaceutical company. Co. is focused on discovering, developing and commercializing small-molecule and protein therapeutics for larger-market as well as orphan indications targeting immunologic diseases. Co.'s drug candidate narsoplimab is the subject of a biologics license application pending before the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Co. has various late-stage clinical development programs in its pipeline, which are focused on: complement-mediated disorders, including immunoglobulin A nephropathy, atypical hemolytic uremic syndrome and COVID-19.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
25,000 |
25,000 |
Total Buy Value |
$0 |
$0 |
$40,500 |
$40,500 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
10,000 |
Total Sell Value |
$0 |
$0 |
$0 |
$64,950 |
Total People Sold |
0 |
0 |
0 |
2 |
Total Sell Transactions |
0 |
0 |
0 |
2 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-04-15 |
4 |
AS |
$15.18 |
$241,392 |
D/D |
(15,900) |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-04-15 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
179,497 |
|
- |
|
Cable Thomas J. |
Director |
|
2016-03-24 |
4 |
AS |
$14.71 |
$29,627 |
D/D |
(2,000) |
49,067 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-03-23 |
4 |
OE |
$4.10 |
$62,201 |
D/D |
15,171 |
163,597 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-03-15 |
4 |
AS |
$15.12 |
$240,414 |
D/D |
(15,900) |
148,426 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-03-15 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
164,326 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-03-08 |
4 |
AS |
$15.03 |
$478,005 |
D/D |
(31,800) |
148,426 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-03-08 |
4 |
OE |
$0.98 |
$31,164 |
D/D |
31,800 |
180,226 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2016-01-14 |
4 |
OE |
$0.98 |
$98,000 |
D/D |
100,000 |
1,703,822 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2016-01-14 |
4 |
OE |
$4.10 |
$41,000 |
D/D |
10,000 |
148,426 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2015-11-23 |
4 |
AS |
$15.00 |
$238,500 |
D/D |
(15,900) |
131,126 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2015-11-23 |
4 |
OE |
$0.98 |
$15,582 |
D/D |
15,900 |
147,026 |
|
- |
|
Cable Thomas J. |
Director |
|
2015-11-18 |
4 |
AS |
$13.73 |
$27,469 |
D/D |
(2,000) |
51,067 |
|
- |
|
Demopulos Peter A Md |
Director |
|
2015-09-04 |
4 |
B |
$12.68 |
$50,238 |
D/D |
3,962 |
185,182 |
2.39 |
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2015-08-18 |
4 |
OE |
$0.98 |
$11,760 |
D/D |
12,000 |
1,603,822 |
|
- |
|
Cable Thomas J. |
Director |
|
2015-07-15 |
4 |
AS |
$18.78 |
$37,556 |
D/D |
(2,000) |
53,067 |
|
- |
|
Kelbon Marcia S. |
VP Patent and General Counsel |
|
2015-07-07 |
4 |
OE |
$2.45 |
$12,500 |
D/D |
5,102 |
131,126 |
|
- |
|
Cable Thomas J. |
Director |
|
2015-03-24 |
4 |
AS |
$24.43 |
$48,991 |
D/D |
(2,000) |
55,067 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2015-01-28 |
4 |
OE |
$0.98 |
$31,360 |
D/D |
32,000 |
1,591,822 |
|
- |
|
Demopulos Gregory A Md |
Chairman, CEO & President |
|
2014-11-02 |
4 |
OE |
$0.98 |
$32,340 |
D/D |
33,000 |
1,559,822 |
|
- |
|
Cable Thomas J. |
Director |
|
2014-09-02 |
4 |
AS |
$15.07 |
$75,330 |
D/D |
(5,000) |
57,067 |
|
- |
|
Demopulos Peter A Md |
Director |
|
2014-06-24 |
4 |
B |
$16.20 |
$99,704 |
D/D |
6,153 |
181,220 |
2.39 |
- |
|
Cable Thomas J. |
Director |
|
2014-06-02 |
4 |
AS |
$11.79 |
$59,004 |
D/D |
(5,000) |
62,067 |
|
- |
|
123 Records found
|
|
Page 5 of 5 |
|
|